[Middle-High Dose of Cyclophosphamide or Conventional Routine Chemotherapy with Increased Dose of Cyclophosphamide Combined with G-CSF for Mobilizing Peripheral Blood Progenitor Cells in Patients with Tumor].

Dao-pei Lu,Kai-yan Liu,Nai-lan Guo,Yuan-kai Shi,Xiao-hui He,Fang-ding Lou,Wan-ming Da,Buo-long Zhang,Liang-xu Wang,Xiao-yan Ke

DOI: https://doi.org/10.3760/j:issn:0253-2727.2003.02.005

2003-01-01

Abstract:OBJECTIVE:To investigate the clinical value of glycosylated G-CSF combined with middle-high dose cyclophosphamide (Cy) or conventional chemotherapy with increased dose of Cy for mobilizing peripheral blood progenitor cells in patients with tumor.METHODS:Thirty patients from four hospitals in Beijing region were enrolled in this clinical study. Diagnoses of the patients were non-Hodgkin' lymphoma (n = 21), Hodgkin disease (n = 1), breast cancer (n = 7) and ovary cancer (n = 1). Autologous peripheral blood progenitor cells (APBPC) were mobilized by middle-high dose Cy or conventional chemotherapy with increased dose of Cy combined with G-CSF. G-CSF was given subcutaneously from the nadir of the white blood cell (WBC) count to the end of PBPC collection. The dosage of G-CSF was 250 microg/d in 29 patients and 500 microg/d in 1 patient. When WBC count was > 5 x 10(9)/L, APBPC were harvested with CS 3000 plus/COBE Spectra.RESULTS:The average dosage of Cy was 3.95 g (2.3 g/m(2)). The doses of G-CSF were 3.1 approximately 6.4 microg x kg(-1) x d(-1). Thirteen patients (43%) were collected twice, 14 patients (47%) three times and 3 patients (10%) four times. All of the patients could tolerate the treatment regimens. Seven patients had bone pain after G-CSF injection and one was severe, one patient had headache and one had nausea and vomiting.CONCLUSION:250 microg glycosylated G-CSF combined with middle-high Cy or conventional chemotherapy with increased dose of Cy combined G-CSF is an optimal method for APBPC mobilization in tumor patients.